Berenberg Initiates Coverage On Harmony Biosciences with Buy Rating, Announces Price Target of $59
Portfolio Pulse from Benzinga Newsdesk
Berenberg analyst Caroline Palomeque has initiated coverage on Harmony Biosciences (NASDAQ:HRMY) with a Buy rating and a price target of $59.
September 07, 2023 | 9:53 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Harmony Biosciences has been initiated with a Buy rating by Berenberg, with a price target of $59.
The initiation of coverage by Berenberg with a Buy rating and a price target of $59 indicates a positive outlook for Harmony Biosciences. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100